あなたの視力を見守る
 
Choose Language
  • French
  • Deutsch
  • Italian
  • Russian
  • Japanese
  • Espanol
  • English
Connect and Share
文字色: 
    Color Color Color Color
フォント: 
    Size Size Size Size
    Join

メインメニュー

メインコンテンツへ移動
サブコンテンツへ移動
  • 学ぶ
  • 治療
  • もっと知る
  • つながる
  • 私たち
  • 寄付

Science of AMD Newsfeed

  • FDA approves faricimab for treatment of wet AMD and DME
  • (English) Novartis Provides Update on Use and Safety of Beovu in Patients With Wet AMD
  • (English) Beovu Approved for Wet AMD in European Union
  • (English) AMD Incidence to Rise by 75% and Affect 77 million Europeans by 2050
  • (English) Opthea OPT-302 Combo Outshines Lucentis Alone
  • (English) Positive phase 2 trial results of anti-VEGF abicipar pegol for treating wet AMD
  • (English) Vitreous separation in wet AMD patients linked to fewer anti-VEGF injections
  • (English) As-needed anti-VEGF regimen shown to be effective for the treatment of wet AMD
  • (English) Greatest vision gains occur during early stages of anti-VEGF treatment for wet AMD
  • (English) Potential Topical Treatment in the Future for Macular Degeneration
  • (English) MicroRNAs Block Abnormal Blood Vessel Growth While Still Maintaining the Health of Normal Vessels
  • (English) New Treatment Approach in Mice Regresses Abnormal Vessels in Wet Macular Degeneration
  • (English) Discussions on the Retina and AMD from the American Academy of Opthalmology 2013: Hear from the Experts
  • (English) New Initiative by the American Academy of Ophthalmology Harnesses Technology to Improve Patient Outcomes
  • レポートをダウンロードする
  • 用語集
  • 連絡先
  • プライバシーポリシー
  • 免責事項
  • 支援団体一覧
The Angiogenesis Foundation - One Broadway, 14th fl, Cambridge, MA 02142, (617) 401-2779 amd@angio.org
This website is certified by Health On the Net Foundation. Click to verify.
「当サイトの医療情報の信憑性は、スイス・ジュネーヴ・HONの基準に準拠しております」